Zepbound for Sleep Apnea: What the Evidence Actually Shows

Yes, Zepbound (tirzepatide) is a real, FDA-approved treatment for obstructive sleep apnea (OSA) — but only for one group of patients: adults with moderate-to-severe OSA who also have obesity. In December 2024, the FDA approved it for that use, making it the first medication ever approved for OSA, a condition that had previously been treated mainly with devices like CPAP ^{[8] [9]}. In the pivotal 52-week trials, tirzepatide reduced the apnea-hypopnea index (AHI) by an estimated 20.0 to 23.8 events per hour more than placebo ^[1].

It is not a cure, and it is not a CPAP substitute. The American Academy of Sleep Medicine (AASM) states plainly that the goal of tirzepatide is not to replace CPAP but to serve as an add-on tool that targets excess weight, and that CPAP should not be stopped without a proper reassessment ^[7]. The approval also comes with limits: the trials lasted 52 weeks, measured AHI rather than heart attacks or deaths, and enrolled only people with moderate-to-severe OSA and obesity ^{[1] [5] [7]}.

What exactly did the FDA approve?

The FDA label for Zepbound lists two indications, both in combination with a reduced-calorie diet and increased physical activity: reducing excess body weight and keeping it off long term in adults with obesity (or overweight plus at least one weight-related condition), and treating moderate to severe obstructive sleep apnea in adults with obesity ^[4].

Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist ^{[4] [5]}. Tirzepatide was first approved in the United States in 2022, and the current label was revised in August 2026 ^[4].

The approval matters because of how common the overlap is. OSA affects roughly 30 million US adults, and obesity is a major risk factor ^[9]. A 2020 review in the International Journal of Obesity, cited by the AASM, found that more than 80% of adults with OSA are overweight and more than 50% meet criteria for obesity ^[7]. Before the label expansion, only 14% of OSA patients in a large claims analysis were receiving any GLP-1, while 66% received device-based treatment such as CPAP ^[9].

What did the SURMOUNT-OSA trials measure?

The evidence behind the approval comes from SURMOUNT-OSA, a master protocol of two phase 3, 52-week, double-blind, placebo-controlled studies ^{[1] [5]}. Trial 1 enrolled adults who were not on positive airway pressure (PAP) therapy at baseline; trial 2 enrolled adults who were on PAP at baseline ^[1]. Everyone was randomized 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks ^[1].

In total, 469 participants were randomized: 234 in trial 1 (114 tirzepatide, 120 placebo) and 235 in trial 2 (120 tirzepatide, 115 placebo) ^[5]. To enter the studies, participants needed moderate-to-severe OSA (AHI of 15 or higher) plus obesity ^[7]. Their starting disease was severe on average: baseline mean AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2, with mean BMI of 39.1 and 38.7 ^[1]. All participants received lifestyle counseling on healthy eating and physical activity ^[7].

The primary endpoint was the change in AHI — the number of apneas and hypopneas per hour of sleep — from baseline ^[1].

How much did AHI improve on tirzepatide?

Both trials showed large reductions in AHI compared with placebo at week 52 ^[1]:

Measure	Trial 1 (not on PAP)	Trial 2 (on PAP)
Baseline mean AHI	51.5 events/hour	49.5 events/hour
AHI change, tirzepatide	−25.3 events/hour (95% CI −29.3 to −21.2)	−29.3 events/hour (95% CI −33.2 to −25.4)
AHI change, placebo	−5.3 events/hour (95% CI −9.4 to −1.1)	−5.5 events/hour (95% CI −9.9 to −1.2)
Treatment difference	−20.0 events/hour (P<0.001)	−23.8 events/hour (P<0.001)

Beyond AHI, the key secondary endpoints — percent change in AHI, body weight, hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure — all improved significantly with tirzepatide versus placebo ^[1]. The most frequent adverse events were gastrointestinal and mostly mild to moderate ^[1]. The trial was funded by Eli Lilly, and Lilly employees were among the authors; it is registered as NCT05412004 on ClinicalTrials.gov ^{[1] [5]}.

Is the benefit just from weight loss?

This is an open question the trials only partly answer. Excess body fat is a major reversible cause of OSA, and weight reduction is known to improve AHI ^{[1] [5]}. A secondary analysis of SURMOUNT-OSA published in Nature Medicine ran a mediation analysis to sort out how much of the cardiometabolic improvement came from weight change versus changes in sleep apnea metrics ^[5].

The analysis reported an independent mediation effect of changes in OSA metrics on hsCRP, insulin resistance (HOMA-IR), and triglycerides ^[5]. For systolic blood pressure, both weight alone and weight plus OSA metrics together had significant mediation effects; for diastolic blood pressure, neither did ^[5]. The authors concluded that treating both sleep-disordered breathing and obesity is likely needed to get the full cardiometabolic benefit ^[5].

That analysis was secondary and post hoc, so it is weaker evidence than the main trial results ^[5]. And the trials did not measure heart attacks, strokes, or deaths — the primary endpoint was AHI ^{[1] [5]}.

What dose does the label specify for sleep apnea?

The FDA label sets the maintenance dosage for OSA at 10 mg or 15 mg injected under the skin once weekly ^[4]. For weight reduction, the maintenance dosage is 5 mg, 10 mg, or 15 mg once weekly ^[4].

Everyone starts the same way regardless of indication: 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg increments after at least 4 weeks on the current dose ^[4]. The 2.5 mg dose is for initiation only and is not approved as a maintenance dose ^[4]. The maximum recommended dosage is 15 mg once weekly ^[4]. The label also states that Zepbound should not be used together with other tirzepatide-containing products or any GLP-1 receptor agonist ^[4].

Zepbound comes as a single-dose pen or vial in strengths from 2.5 mg to 15 mg per 0.5 mL, and as a multi-dose vial or KwikPen delivering four doses ^[4].

What are the side effects and warnings?

Zepbound carries a boxed warning about thyroid C-cell tumors seen in rats; the human relevance is undetermined ^[4]. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, in those with Multiple Endocrine Neoplasia syndrome 2, and in anyone with serious hypersensitivity to tirzepatide or its ingredients ^[4].

Label warnings include severe gastrointestinal reactions (it is not recommended in severe gastroparesis), acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia when combined with insulin or insulin secretagogues, diabetic retinopathy progression in people with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation ^[4]. The label advises patients to tell providers about planned surgeries ^[4].

The most common adverse reactions, reported in 5% or more of patients, are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[4]. Zepbound delays stomach emptying and can affect absorption of oral medications ^[4]. It may cause fetal harm in pregnancy, and users of oral contraceptives are advised to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase ^[4].

The AASM adds practical cautions: use care in people with gastroparesis, pancreatitis, gallbladder disease, kidney failure, or eating disorders; no labs are required by the FDA label, though many experts suggest a baseline metabolic panel, especially with chronic kidney disease ^[7]. The AASM also warns against compounded tirzepatide sold online or direct-to-consumer, because it is not FDA-regulated and may not contain the correct active ingredient ^[7].

Can Zepbound replace CPAP?

No — and the major sleep medicine body says so directly. The AASM states that the goal of tirzepatide therapy is not to replace CPAP or other traditional OSA treatments but to add a tool that targets excess weight, and that CPAP should not be discontinued without proper reassessment ^[7]. The AASM describes tirzepatide as a tool, not a cure, that works best alongside lifestyle changes and continued OSA therapy ^[7].

There is also no head-to-head randomized comparison of tirzepatide versus CPAP in the published SURMOUNT-OSA trials ^[1]. Trial 2 actually enrolled people already on PAP, and they still improved on top of that therapy ^[1].

The reassessment mechanism exists, though. AASM guidance says follow-up polysomnography or a home sleep apnea test may be used after a clinically significant weight change — 10% to 20% — since OSA diagnosis or the start of treatment ^[8]. In other words, sleep testing after major weight change is the accepted way to recheck OSA severity, not simply stopping CPAP.

The AASM also frames tirzepatide as potentially long-term therapy, comparable to blood pressure medication, and notes that board certification in obesity medicine is not required to prescribe it — but prescribers must manage side effects, titration, nutrition, and drug interactions ^[7].

What is actually happening in US practice?

A Komodo Health analysis of claims from nearly 20 million adults diagnosed with OSA gives an early picture of real-world use ^[9].

After the December 2024 approval, new tirzepatide starts among OSA patients rose 16% in the first six months (January through June 2025) ^[9]. The drug is being started early in the treatment course: about 30% of newly diagnosed OSA patients who started tirzepatide did so within 30 days of diagnosis, 47% within 60 days, and only 3% after 270 or more days ^[9]. Initiation rates were highest among ages 45 to 54 (91 per 1,000 OSA patients), followed by 35 to 44 (87 per 1,000), and lowest among those 75 and older (37 per 1,000) ^[9].

Prescribing is overwhelmingly a primary care activity: about 84% of tirzepatide prescriptions for OSA patients were written by primary care clinicians — family medicine 31%, nurse practitioners 24%, internal medicine next — while sleep specialists wrote less than 1% ^[9].

The analysis also found changes in CPAP patterns. Among OSA patients with no prior CPAP use, 4% of those who started tirzepatide began CPAP within six months, versus 22% of those without GLP-1 exposure — an 83% relative difference in new CPAP starts ^[9]. Among existing CPAP users, 26% of tirzepatide initiators had a six-month gap with no CPAP-related claims, versus 15% of matched non-users — a 75% relative difference ^[9]. Komodo notes that a claims gap is a proxy and cannot confirm clinical discontinuation ^[9].

Will insurance or Medicare pay for it?

Coverage is the biggest practical barrier. Eli Lilly’s list price for Zepbound is $1,086.37 per fill, but what a patient pays out of pocket depends on the plan ^[7]. Coverage varies by plan and provider, and many insurers require prior authorization ^[7].

On Medicare: some Medicare drug plans may cover Zepbound for treating OSA but not for weight loss alone ^[7]. As of the AASM article published in September 2025, the Centers for Medicare and Medicaid Services was considering expanding coverage of anti-obesity medications beginning in 2026 ^[7].

Commercial coverage is not guaranteed either. CVS Health excluded Zepbound from its covered drug list as of July 1, 2025 ^[7]. The label expansion to OSA did open a payer-supported access route for people with obesity-associated OSA that did not exist when the drug was approved for weight loss alone ^[9].

For prior authorization, the AASM suggests clinicians submit a one-page letter of medical necessity citing the FDA approval and the patient’s eligibility, document comorbidities, prior therapies, and BMI trends, use organized templates, and assign dedicated staff to the process ^[7].

What happens if treatment stops?

The AASM cautions that stopping tirzepatide may affect the AHI reductions and OSA severity improvements achieved while on the drug ^[7]. The SURMOUNT-4 trial, published in JAMA and cited by the AASM, found that continued pharmacotherapy was needed to prevent weight regain and sustain cardiometabolic improvement ^[7]. Patients should be counseled that therapy may be long-term ^[7].

What are the limits of the evidence?

The honest picture includes several constraints:

• The trials ran for 52 weeks only — there is no longer-term randomized data in these studies ^{[1] [5]}.
• The primary endpoint was AHI, not cardiovascular events or mortality ^{[1] [5]}.
• The population was limited to adults with moderate-to-severe OSA (AHI of 15 or higher) and obesity; the results do not automatically extend to mild OSA or to people without obesity ^[7].
• The trial was funded by Eli Lilly, with Lilly employees among the authors ^[1].
• The cardiometabolic findings beyond the main endpoints, including the mediation analysis, were secondary or post hoc ^[5].

Epidemiologic estimates cited by Komodo suggest about 39% of adults with OSA have moderate-to-severe disease, and 43% to 54% of those meet obesity criteria — the group the drug is indicated for ^[9].

What are the practical next steps?

The AASM’s guidance points to a few concrete steps for anyone considering this treatment. The conversation belongs with the clinician managing the OSA, and CPAP should not be stopped without reassessment ^[7]. Repeat sleep testing after a 10% to 20% weight change is the established mechanism for rechecking OSA severity ^[8].

The AASM recommends a multidisciplinary approach — obesity medicine clinicians or clinics, registered dietitians, behavioral health professionals, and trained staff to navigate coverage ^[7]. It also advises avoiding compounded tirzepatide sold online or through direct-to-consumer platforms ^[7]. The AASM has published a 2026 report, “Advancing Healthy Weight Management in Sleep Medicine,” with recommendations for how sleep medicine practices should engage in obesity management ^[8].

Sources

1. New England Journal of Medicine. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
2. PubMed Central. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
3. US Food and Drug Administration. Zepbound (tirzepatide) new drug application approval document.
4. US Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information.
5. Nature Medicine. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
6. SLEEP. Participants with Improvement in OSA Severity Following Treatment: A Post Hoc Analysis of SURMOUNT-OSA Studies.
7. American Academy of Sleep Medicine. What clinicians should know about prescribing tirzepatide for sleep apnea.
8. American Academy of Sleep Medicine. Obesity Management Resources for Sleep Medicine.
9. Komodo Health. FDA’s First GLP-1 Approval for Sleep Apnea May Reduce Reliance on CPAP. February 9, 2026.
10. Endocrinology Advisor. Tirzepatide Linked to Reduced CPAP Use and Mortality in Patients With OSA.
11. Centers for Medicare & Medicaid Services. Information for Part D Plans.
12. NBC Chicago. Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, Health Department agency says. January 8, 2025.
13. Journal of Diabetes. The Role of Incretins in Obstructive Sleep Apnea “GLP1RAs and GLP1RA/GIPRAs in OSA”. 2025.
14. Diabetes, Obesity and Metabolism. Tirzepatide Combined With Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnoea Syndrome With Comorbid Obesity: Effects on Weight, Daytime Sleepiness, and Cognitive Performance. 2026.